Symbiotec Pharmalab's US FDA inspection yields VAI classification

Symbiotac Pharmalab receives VAI classification from US FDA after inspection. The Establishment Inspection Report (EIR) for its Pithampur SEZ facility indicates observations requiring corrective actions. VAI means Voluntary Action Indicated, potentially delaying US market expansion. Regulatory compliance focus intensifies near-term operational risks.

📊 STOCKS: $SYMBIOTEC | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #FDA